The absence of selective pharmacological tools is a major barrier to the in vivo study of microglia. To address this issue, we developed a G q -and G i -coupled Designer Receptor Exclusively Activated by a Designer Drug (DREADD) to enable selective stimulation or inhibition of microglia, respectively. DREADDs under a CD68 (microglia/ macrophage) promoter were intrathecally transfected via an AAV9 vector. Naïve male rats intrathecally transfected with G q (stimulatory) DREADDs exhibited significant allodynia following intrathecal administration of the DREADD-selective ligand clozapine-N-oxide (CNO), which was abolished by intrathecal interleukin-1 receptor antagonist. Chronic constriction injury-induced allodynia was attenuated by intrathecal CNO in male rats intrathecally transfected with G i (inhibitory) DREADDs. To explore mechanisms, BV2 cells were stably transfected with G q or G i DREADDs in vitro. CNO treatment induced pro-inflammatory mediator production per se from cells expressing G q -DREADDs, and inhibited lipopolysaccharide-and CCL2-induced inflammatory signaling from cells expressing G i -DREADDs. These studies are the first to manipulate microglia function using DREADDs, which allow the role of glia in pain to be conclusively demonstrated, unconfounded by neuronal off-target effects that exist for all other drugs that also inhibit glia. Hence, these studies are the first to conclusively demonstrate that in vivo stimulation of resident spinal microglia in intact spinal cord is a) sufficient for allodynia, and b) necessary for allodynia induced by peripheral nerve injury. DREADDs are a unique tool to selectively explore the physiological and pathological role of microglia in vivo.
Introduction
Microglia, the resident macrophages of the central nervous system (CNS), have a key role in maintaining homeostasis and in driving many CNS pathologies, including persistent pain (Grace et al. 2014; Ji et al. 2016; Old et al. 2015; Salter and Stevens 2017) . Precise delineation of their function in vivo has been hindered by a lack of tools to selectively activate or inhibit microglia. There are no strategies in routine use to selectively activate microglia without activating other cell types as well. In addition, several approaches have been used to inhibit microglia, but all are flawed with respect to specificity. For example, pharmacological agents such as minocycline, which do inhibit microglia (Yrjänheikki et al. 1998) , also have inhibitory effects on other cells in the CNS like neurons, astrocytes and T cells (e.g., (González et al. 2007; Song et al. 2016; Szeto et al. 2011) ). Selective depletion methods have been described, such as CSF-1R antagonism (Elmore et al. 2014) , or credriven expression of the diphtheria toxin receptor in microglia (Parkhurst et al. 2013) . However, these methods widely perturb the CNS, as cytokine production and/or astrogliosis is reported. These offtarget effects may confound interpretations regarding the role of microglia in physiological and pathological processes.
We have recently reported that hM4Di Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) can be used to inhibit microglia in vitro and in vivo (Grace et al. 2016a) . Once expressed under a cell-specific promoter, DREADDs can be remotely activated with clozapine-N-oxide (CNO) (Armbruster et al. 2007 ). Gilinked signaling was predicted to attenuate microglial reactivity because activation of the M4 muscarinic receptor (the Gi DREADD progenitor (Armbruster et al. 2007) ) inhibits Ca 2+ influx in parasympathetic neurons (Cuevas and Adams 1997) , a process associated with decreased proinflammatory cytokine production in microglia (Hayashi et al. 2011; Hoffmann et al. 2003) . When spinal microglia were transfected with hM4Di DREADDs under a CD68 promoter in vivo, treatment with CNO prevented and reversed morphine-induced persistent sensitization in male rats (Grace et al. 2016a) . CNO also attenuated inflammatory gene expression in hM4Di + BV-2 cells (a microglia cell line) that were stimulated with the danger signal HMGB1 (Grace et al. 2016a; Lacagnina et al. 2017) . Inflammatory mediators, such as nitric oxide (NO) and interleukin-1β (IL-1β) promote neuronal hyperexcitability in the spinal dorsal horn (Grace et al. 2014 (Grace et al. , 2016b . However, it is not known whether these results apply to neuropathic pain per se, and extend to other BV-2 cell stimuli in vitro. hM3Dq DREADDs have also been developed that mobilize intracellular calcium through Gq proteins (Armbruster et al. 2007 ). As noted above, increased intracellular Ca 2+ is a substrate for microglial activation and cytokine release (Hoffmann et al. 2003) . Whether hM3Dq DREADDs can activate microglia is unknown.
The first aim of this study was to determine whether activation or inhibition of microglia via DREADDs could influence nociceptive hypersensitivity. The second aim was to validate behavioral results in microglia cell cultures by determining whether DREADD activation or inhibition would influence cytokine transcription and translation. Our data indicate that DREADDs can be used to modulate microglial activity in vitro and in vivo.
Materials and methods

Subjects
Pathogen-free adult male Sprague Dawley rats (n = 6 rats/group for each experiment; 10-12 weeks old on arrival; Envigo Labs, Indianapolis, IN) were used in all experiments. Rats were housed in temperature-controlled (23 ± 3°C) and light-controlled (12 h light:-dark cycle; lights on at 07:00 h) rooms with standard rodent chow and water available ad libitum. All procedures were approved by the Institutional Animal Care and Use Committee of the University of Colorado Boulder.
DREADDs and drugs
pAAV-CD68-hM4Di-mCherry, pAAV-CD68-hM3Dq-mCherry, pAAV-CD68-EGFP (control), pLenti6.3-CMV hM4Di, and pLenti6.3-CMV hM3Dq plasmids were generated as previously described (Grace et al. 2016a ) (gifted by D.J. Urban and B.L. Roth). pAAV plasmids were packaged in serotype 9 by the UNC Vector Core Facility. Clozapine-Noxide (CNO; Enzo Life Sciences, Farmingdale, NY) was obtained commercially, while IL-1ra was gifted by Amgen (Thousand Oaks, CA). Vehicles were DMSO (1.5% vol/vol) for CNO and sterile saline for IL1ra.
Chronic constriction injury (CCI) surgery
Neuropathic pain was induced using the CCI model of sciatic nerve injury (Bennett and Xie 1988) . Surgery was performed at the mid-thigh level of the left hindleg as previously described (Grace et al. 2010) . In brief, animals were anesthetized with isoflurane. The shaved skin was treated with Nolvasan and the surgery was performed aseptically. Four sterile chromic gut sutures (cuticular 4-0 WebGut, Patterson Veterinary, Devens, MA) were loosely tied around the gently isolated sciatic nerve. Animals were monitored post-operatively until fully ambulatory, prior to return to their home cage.
Mechanical allodynia
All testing was conducted blind with respect to group assignment. Rats received at least three 60-min habituations to the test environment prior to behavioral testing. The von Frey test (Chaplan et al. 1994 ) was performed as previously described (Grace et al. 2010) . A logarithmic series of 10 calibrated Semmes-Weinstein monofilaments (von Frey hairs; Stoelting, Wood Dale, IL) were applied randomly to the left versus right hind paws to define the threshold stimulus intensity required to elicit a paw withdrawal response. Log stiffness of the hairs ranged from manufacturer-designated 3.61 (0.40 g) to 5.18 (15.14 g) filaments. The behavioral responses were used to calculate absolute threshold (the 50% probability of response) by fitting a Gaussian integral psychometric function using a maximum-likelihood fitting method (Harvey 1986; Treutwein and Strasburger 1999) .
Acute and chronic catheter implantation
The method of construction and implantation of the acute and indwelling intrathecal catheters was based on that described previously (Milligan et al. 1999) . In brief, intrathecal operations were conducted under isoflurane anesthesia by threading sterile polyethylene-10 tubing (PE-10 Intramedic Tubing; Becton Dickinson Primary Care Diagnostics, Sparks, MD, USA) guided by an 18-gauge needle between the L5 and L6 vertebrae. The catheter was inserted such that the proximal catheter tip lay over the lumbosacral enlargement. For acute intrathecal drug delivery, catheters were removed immediately following drug delivery. For indwelling catheters, the needle was removed and the catheter was sutured to the superficial musculature of the lower back. The catheters were 17 cm in length.
Intrathecal and intraperitoneal drug administration
For acute intrathecal drug delivery, the catheters were pre-loaded with drugs at the distal end in a total volume and delivered over 20-30 s once the catheter was in position. Acute intrathecal doses were as follows, DREADDs: 1.2 × 10 13 vg in 8 μl (injected 4 weeks prior to CNO treatment); CNO 60 μg in 10 μl; IL-1ra: 100 μg in 10 μl. For repeated CNO treatment, 60 μg in 10 μl was delivered daily for 3 days. Intraperitoneal CNO was administered at 1 mg/kg. We have previously validated microglial expression of DREADDs when transfected via an AAV9 vector (Grace et al. 2016a ).
Immunohistochemistry
After 3 days of CNO treatment, rats were deeply anesthetized with sodium pentobarbital and transcardially perfused with saline, followed by 4% paraformaldehyde/0.1 M phosphate buffer. Spinal cords were dissected and postfixed for 24 h in 4% paraformaldehyde/0.1 M phosphate buffer, and cryoprotected in 30% sucrose with 0.1% azide at 4°C until slicing. Lumbar spinal cords were freeze-mounted in OCT, and cut at 20 μm frozen sections. Sections were permeabilized with 0.3% hydrogen peroxide, blocked for 1 h with 10% NGS, 0.3% Triton-X in PBS, and then incubated overnight at 4°C for 24 h in 2% normal goat serum together with mouse anti-rat CD11b (1:1000; Bio-Rad, Hercules, CA). Slides were then washed, incubated in the secondary antibody at 1:200 (Goat anti mouse biotin, Jackson Immuno Research, West Grove, PA) for 2 h. Sections were once again washed, incubated in ABC solution (Vector Laboratories, Burlingame, CA) for 2 h, washed, and incubated in inactive DAB (Sigma) for 10 min. DAB was then activated with B-D glucose (10 mg/ml) and slides were incubated for 8 min, washed, and dried overnight. Slides were dehydrated in increasing concentrations of EtOH (50, 70, 95 and 100%) , cleared in Citrisolv, dried and covered with DPX mountant (Sigma).
Images were acquired using an Olympus BX61 microscope (Olympus, Center Valley, PA) with Suite Cell Sens Dimension software (Olympus). All images were taken using the same exposure and settings, and captured at 20× magnification. Images were converted to 32 bit, corrected for threshold, and densitometry was conducted using NIH Image J software, while blinded to treatment conditions. Four images per animal were taken with 3 selections within each image analyzed, resulting in 12 areas of analysis per animal. Data are expressed as total area positive for staining within the selected area.
BV-2 transfection, cell culture, and treatments
Mouse microglia BV-2 cells were grown in DMEM medium supplemented with 10% FBS. Cells were seeded at a density of 1 × 10 4 cells/ ml in 35 mm dish. When cells reached~60% confluence, the medium was aspirated and 0.5 ml of pLenti6.3-CMV hM3Dq or pLenti6.3-CMV hM4Di lenti-virus medium (multiplicity of infection = 10 4 ) and 8 μg/ ml polybrene were added for transfection. After 24 h transfection, the virus was removed and the cells were cultured in DMEM medium supplemented with 10% FBS for additional 24 h. The pLenti6.3-CMV hM3Dq or pLenti6.3-CMV hM4Di positive cells were then selected by DMEM medium supplemented with 10% FBS and 10 μg/ml puromycin. Positive colonies were picked up and were further cultured. The pLenti6.3-CMV hM3Dq and pLenti6.3-CMV hM4Di positive cells were further confirmed by V5 tag western blotting.
pLenti6.3-CMV hM3Dq or pLenti6.3-CMV hM4Di positive cells were seeded into 96 well plates at a density of 5 × 10 4 cells/ml in DMEM medium supplemented with 10% FBS. After 24 h, all cells were washed. pLenti6.3-CMV hM3Dq cells were incubated with a concentration range of CNO (0, 50, 100 μM) in serum-free DMEM medium for 24 h. The CNO concentrations used did not adversely affect cell viability (Fig. S1 ). pLenti6.3-CMV hM4Di cells were incubated with a concentration range of LPS (0, 20, 200, 2000 μg/ml) or CCL2 (0, 50, 100 μg/ml), together with 0 or 50 μM of CNO in serum-free DMEM medium for 4 or 24 h. Non-transfected were treated with a concentration range of CNO (0-400 μM), together with a LPS (0 or 200 ng/ml) in serum-free DMEM medium for 24 h. Cells were collected by centrifugation for RT-PCR, whereas supernatants were collected for NO and cytokine analysis.
RT-PCR
Total RNA was isolated using a standard method of phenol:chloroform extraction (Chomczynski and Sacchi 1987) . cDNA amplification was performed using Quantitect SYBR Green PCR kit (Qiagen) in iCycler iQ 96-well PCR plates (Bio-Rad) on a MyiQ single Color RealTime PCR Detection System (Bio-Rad). Primer sequences (GenBank, National Center for Biotechnology Information; www.ncbi.nlm.nih.gov) are as follows, Gapdh: F: GGAGAAACCTGCCAAGTATG, R: GTCATTG AGAGCAATGCCAG; Nos2: F: GGAGTGACGGCAAACATGACT, R: TCG ATGCACAACTGGGTGAAC; Il1b: F: TGCTGTCGGACCCATATGAG, R: ATCCACACTCTCCAGCTGCA. Each sample was measured in duplicate by using the MyiQ single Color Real-Time PCR Detection System (BioRad). Threshold for detection of PCR product was set in the log-linear phase of amplification and the threshold cycle (CT) was determined for each reaction. The level of the target mRNA was quantified relative to the housekeeping gene (GAPDH) using the ΔΔCT method (Livak and Schmittgen 2001 ). GAPDH was not significantly different between treatments.
NO assay
The NO (nitrite) concentration in the culture supernatant was determined by the 2,3-diaminonaphthalene-based fluorescent method (Misko et al. 1993) . The plate was read on a Beckman Coulter DTX880 reader (λ ex 365 nm, λ em 430 nm).
ELISA
A total of 50 μl of cell culture supernatants were used for the assays. Cytokine levels were determined using commercially available rat TNF, IL-1β, and IL-6 ELISA kits (R&D Systems). The assays were performed according to the manufacturer's instructions. Bradford protein assays were also performed to determine total protein concentrations in sonication samples. The analyte concentrations are presented as nanograms per mg of total protein.
Cell viability assay
Crystal violet staining was used to determine cell viability as described previously (Selfridge et al. 2015; Wang et al. 2013 ). Twentyfour hours after treatment, cells were fixed by 3.7% paraformaldehyde (PFA) for 5 min and then stained by 0.05% crystal violet for 30 min. The plates were subsequently washed 2 times with tap water and dried for 30 min at room temperature. 200 μl of ethanol was added to each well, and the plates were shaken for 15 min at room temperature to dissolve the dye. Absorbance at 540 nm was measured with a Beckman Coulter Fig. 1 . Spinal microglia inhibition via CD68-hM4Di attenuates CCI-allodynia and CD11b upregulation in vivo. (a) Naïve rats were transfected with intrathecal hM4Di or control DREADDs. Two weeks later, CCI was performed on all rats. After a further two weeks, all rats received a single intrathecal dose of CNO (60 μg). Von Frey thresholds were determined prior to CCI (baseline; BL), prior to CNO (0 h; 14 days post CCI), and across a 24 h timecourse after CNO injection. (b) CD11b density was quantified in the ipsilateral dorsal horn of lumbar spinal cords from naïve rats, nerve-injured rats expressing control DREADD and treated with CNO for 3 days (60 μg/day), and nerve-injured rats expressing hM4Di DREADD and treated with CNO for 3 days. Representative images of ipsilateral dorsal horn of lumbar spinal cord are shown for (c) naïve rats (d) nerveinjured rats expressing control DREADD and treated with CNO for 3 days, and (e) nerve-injured rats expressing hM4Di DREADD and treated with CNO for 3 days. Data are presented as mean ± SEM; n = 6/group; *P < 0.05, ***P < 0.001.
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DTX880 reader (Fullerton, CA, USA).
Statistics
Data from the von Frey test were analyzed as the interpolated 50% thresholds (absolute threshold) in log 10 of stimulus intensity (monofilament stiffness in milligrams × 10). Baseline values were compared between groups using a one-way ANOVA. Differences between treatment groups were determined using repeated measures 2-way ANOVA, followed by Tukey or Sidak post hoc tests where appropriate.
Differences in cytokine levels were determined using 1-way ANOVA or 2-way ANOVA, followed by Dunnett's or Sidak post hoc tests, where appropriate. Differences in gene expression were determined using 2-way ANOVA and Sidak post hoc tests, while differences in densitometry were determined using 1-way ANOVA and Tukey post hoc tests. Statistical comparisons are indicated on the figures for clarity and ± standard error of the mean. Statistical significance was set at P < 0.05. P.M. Grace et al. Experimental Neurology 304 (2018) 125-131 3. Results
hM4Di inhibition of microglia reverses neuropathic pain
To test whether DREADD inhibition of spinal microglia could reverse established neuropathic pain, rats were transfected with intrathecal CD68-hM4Di or the control vector CD68-eGFP. We have previously validated spinal microglial expression of DREADDs when transfected via an AAV9 vector (Grace et al. 2016a) . Two weeks after CCI surgery, a single intrathecal dose of CNO selectively reversed allodynia in those rats expressing hM4Di versus control ( Fig. 1a ; time x treatment: F 4,36 = 34.36, P < 0.001; time: F 4,36 = 41.05, P < 0.001; treatment: F 1,9 = 61.35, P < 0.001). Allodynia was rapidly reversed within 2 h (P < 0.001), remained reversed through 6 h (P < 0.001), and had returned by 24 h. Intraperitoneal CNO also reversed allodynia over a similar timecourse (data not shown).
We quantified CD11b density in the lumbar ipsilateral dorsal horns ( Fig. 1b-e ; F 2,9 = 33.45, P < 0.001). As expected, CD11b was upregulated by CCI in rats expressing the control construct and treated with CNO for 3 days, relative to naïve (P < 0.001). In comparison, 3 days of CNO treatment downregulated CD11b in rats with CCI and expressing the hM4Di DREADD (P < 0.05).
hM4Di inhibition of BV-2 microglia attenuates pro-inflammatory mediator production
The final experiments aimed to test whether inhibition of microglia could attenuate inflammation. BV-2 cells were transfected with hM4Di DREADDs and exposed to a concentration range of LPS (Fig. 2a-d) . LPS activates TLR4, which has a wide-ranging role in pain (Lacagnina et al. 2017) . CNO treatment attenuated expression of Nos2 mRNA (LPS treatment x CNO treatment: F 3,32 = 9.00, P < 0.001; LPS treatment: F 3,32 = 141.3, P < 0.001; CNO treatment: F 1,32 = 22.67, P < 0.001) and NO (LPS treatment x CNO treatment: F 3,32 = 65.28, P < 0.001; LPS treatment: F 3,32 = 435, P < 0.001; CNO treatment: F 1,32 = 230.5, P < 0.001), as well as Il1b mRNA (LPS treatment x CNO treatment: F 3,32 = 13.4, P < 0.001; LPS treatment: F 3,32 = 64.42, P < 0.001; CNO treatment: F 1,32 = 39.09, P < 0.001) and IL-1β (LPS treatment x CNO treatment: F 3,32 = 15.47, P < 0.001; LPS treatment: F 3,32 = 120.7, P < 0.001; CNO treatment: F 1,32 = 54.76, P < 0.001).
To test whether hM4Di DREADDs could attenuate activation from a stimulus that was relevant to neuropathic pain, cells were treated with a concentration range of CCL2 (Fig. 2e-h ). CCL2 is a putative neuronto-microglia signal in neuropathic pain, as microglia express CCR2 (Abbadie et al. 2003; Bose et al. 2016; Feng et al. 2017; Tian et al. 2017; Xu et al. 2017) . CNO treatment attenuated expression of Nos2 mRNA (CCL2 treatment x CNO treatment: F 2,24 = 56.12, P < 0.001; CCL2 treatment: F 2,24 = 71.6, P < 0.001; CNO treatment: F 1,24 = 79.64, P < 0.001) and NO (CCL2 treatment x CNO treatment: F 2,24 = 73.53, P < 0.001; CCL2 treatment: F 2,24 = 113.7, P < 0.001; CNO treatment: F 1,24 = 75.02, P < 0.001), as well as Il1b mRNA (CCL2 treatment x CNO treatment: F 2,23 = 47.51, P < 0.001; CCL2 treatment: F 2,24 = 47.04, P < 0.001; CNO treatment: F 1,23 = 49.44, P < 0.001) and IL-1β (CCL2 treatment x CNO treatment: F 2,24 = 10.02, P < 0.001; CCL2 treatment: F 2,24 = 19.57, P < 0.001; CNO treatment: F 1,24 = 6.954, P < 0.05). CNO had no independent effect on LPS-induced NO release in control BV-2 cells at the concentrations used (Fig.  S1 ).
hM3Dq stimulation of microglia induces IL-1-dependent allodynia
This experiment aimed to test whether activation of spinal microglia with DREADDs is sufficient to induce hindpaw allodynia. Naïve rats were transfected with intrathecal CD68-hM3Dq or the control construct. A single intrathecal dose of CNO selectively induced allodynia in those rats expressing hM3Dq versus control ( Fig. 3 ; time x treatment: F 4,40 = 3.50, P < 0.05; time: F 4,40 = 7.76, P < 0.001; treatment: F 1,10 = 10.45, P < 0.01). Allodynia slowly developed over 4 h (P < 0.05), peaking at 6 h (P < 0.001), and had resolved by 24 h. Intraperitoneal CNO also induced allodynia over a similar timecourse (data not shown).
To test whether CD68-hM3Dq-mediated allodynia was dependent on IL-1, a prototypical pronociceptive cytokine, IL-1ra was administered 2 h after CNO. The drug administrations were timed to overlap the half-lives of CNO (~6 h) with IL-1ra (~4 h). IL-1ra administration completely prevented the induction of allodynia by hM3Dq/CNO ( Fig. 3 ; time x treatment: F 4,40 = 4.45, P < 0.01; time: F 4,40 = 11.58, P < 0.001; treatment: F 1,10 = 12.19, P < 0.01). Spinal microglia stimulation via CD68-hM3Dq induces IL-1-dependent allodynia in vivo. Naïve rats were transfected with intrathecal hM3Dq or control DREADDs. Four weeks later, all rats received a single intrathecal dose of CNO (60 μg). Intrathecal IL-1ra (100 μg) was administered 2 h after CNO. Von Frey thresholds were determined prior to (baseline; BL), and across a 24 h timecourse after CNO injection. Data are presented as mean ± SEM; n = 6/group; *P < 0.05, ***P < 0.001. P.M. Grace et al. Experimental Neurology 304 (2018) 125-131 3.4. hM3Dq stimulation induces pro-inflammatory mediators in BV-2 cells
The next experiment aimed to test whether activation of microglia with DREADDs induces production of proinflammatory mediators that have a known role in pain. BV-2 cells were transfected with hM3Dq DREADDs and exposed to a concentration range of CNO. The CNO treatment dose-dependently increased release of NO ( Fig. 4a ; F 2,12 = 100.8, P < 0.001), TNF ( Fig. 4b; F 2 ,12 = 13.21, P < 0.001), IL-1β ( Fig. 4c; F 2 ,11 = 23.46, P < 0.001) and IL-6 ( Fig. 4d ; F 2,11 = 19.32, P < 0.001).
Discussion
We found that inhibition of spinal microglia via hM4Di DREADDs attenuated established allodynia and CD11b expression in the dorsal horn of the lumbar spinal cord after peripheral nerve injury. Furthermore, these DREADDs attenuated inflammatory signaling induced by LPS and CCL2 in vitro, complementing similar results with HMGB1 (Grace et al. 2016a) . In contrast, activation of spinal microglia via hM3Dq DREADDs induced allodynia in naïve rats, which could be prevented by inhibiting IL-1 signaling. Activation of hM3Dq DREADDs also induced release of inflammatory mediators in vitro. The output of cytokines via hM3Dq is consistent with microglial activation (Grace et al. 2014; Ji et al. 2016 ). Thus, DREADDs may be a useful strategy to selectively activate microglia in vivo.
DREADDs were targeted to microglia using a CD68 promoter. CD68 was selected because of its short promoter sequence, which is optimal for vectors with limited packaging capacity such as AAV. CD68 is not uniquely expressed by microglia, but also by macrophages. Although recently challenged (Gu et al. 2016; Guan et al. 2016) , monocytes may infiltrate the spinal dorsal horn after peripheral nerve injury (Echeverry et al. 2011; Sweitzer et al. 2002; Zhang et al. 2007 ). Therefore, we injected the DREADDs prior to CCI to exclude any possible contribution from leukocytes. However, this design does not restrict microglial proliferation, which was recently shown to contribute to nociceptive hypersensitivity after peripheral nerve injury (Gu et al. 2016) . Because CD68 also has a specialized role in phagocytosis (Zotova et al. 2013) , it is further possible that only a subset of microglia express DREADDs after transfection. While this strategy is still sufficient to induce behavioral changes, approaches that use more generic promoters, such as Iba1, may lead to wider expression. The recent development of creinducible DREADDs (Zhu et al. 2016 ) may also allow for microgliaselective targeting.
CNO was used to activate the DREADDs. It was recently reported that the metabolite clozapine is responsible for the activity of CNO in vivo (Gomez et al. 2017) . Clozapine is anti-nociceptive, but at higher doses than those used here (Schreiber et al. 1999) . Furthermore, our in vivo experimental design excludes an independent anti-or pro-nociceptive effect of CNO, as the control group received pAAV-CD68-EGFP and CNO treatment. Nevertheless, newer approaches have replaced CNO with other drugs, such as compound 21 and KORD, that have minimal off-target activity (Roth 2016) .
Finally, these data further support a fundamental role for microglia in pain in male rats. We show for the first time that selectively activating spinal microglia is sufficient to induce hindpaw allodynia. Furthermore, activation of microglia with DREADDs results in inflammation in vitro and in vivo, which is consistent with their response to microorganisms or to tissue damage (Salter and Stevens 2017) . Future studies may confirm these results in primary microglia cultures. While we show that in situ activation of microglia is sufficient to induce pain, others have adoptively transferred ex vivo activated microglia to validate a specific activation signal (Tsuda et al. 2003) . We also show that microglia are necessary for neuropathic pain, as DREADD inhibition reverses allodynia in vivo, and attenuates inflammatory signaling to chemical challenge in vitro. The extent to which DREADD inhibition attenuates microglia proliferation and activated morphology may be investigated in future studies. The temporal control of DREADD activation through CNO is another advantage over other strategies like adoptive transfer. As recent studies have concluded that microglia are not participants in neuropathic pain in females (Sorge et al. 2015) , DREADDs may be a useful tool to confirm these findings in the future.
Together with our prior study (Grace et al. 2016a) , we report that hM3Dq and hM4Di DREADDs can be used to activate and inhibit microglia, respectively. Future studies may investigate the intracellular signaling pathways that are engaged by Gi and Gq DREADDs. Due to the selectivity of DREADDs, this tool may provide an advantage over other pharmacological and depletion methods. Therefore, DREADDs are a unique tool to selectively explore the physiological and pathological role of microglia in vivo.
Supplementary data to this article can be found online at https:// doi.org/10.1016/j.expneurol.2018.03.005.
